---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-148796"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2026-04-09T23:59:59+00:00"
generated_at: "2026-05-15T06:46:54.544566+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Forte Biosciences prices $150M public offering of 5.7M shares at $26.27/share

## Summary
- Pricing of 5,709,936 shares at $26.27 per share for gross proceeds of ~$150M.
- Underwriters have 30-day option to buy up to 856,490 additional shares.
- Offering expected to close April 10, 2026; net proceeds ~$141M.
- Proceeds to fund working capital and clinical development of autoimmune product candidate.
- Strategic investment from argenx BV noted; Guggenheim and Barclays are joint book-runners.

## SEC filing metadata
- accession: 0001193125-26-148796
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2026-04-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312526148796/0001193125-26-148796-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312526148796/d128424d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-148796
- JSON: https://secwatch.observer/filing/0001193125-26-148796.json
- Plain text: https://secwatch.observer/filing/0001193125-26-148796.txt

## Source-grounded claims
- claim_id: 8bc38495397e13b982f2c56b539bae8df7cec831
  claim: Forte Biosciences, Inc. entered into Underwriting Agreement with Guggenheim Securities, LLC valued at approximately $150 million (effective 2026-04-08).
  evidence_excerpt: On April 8, 2026, Forte Biosciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Guggenheim Securities, LLC as representative (the “Representative”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering (the “Offering”) of 5,709,936 shares of the Company’s common stock, par value $0.001 per share, at a price to the public of $26.27 per share (the “Shares”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419041/000119312526148796/0001193125-26-148796-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.